PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
18310964-9	2008	Plasma insulin as well as fibrinogen were significantly reduced by delapril/manidipine (-17.8 pmol/l, p=0.047 and -67.5 mg/dl, p=0.021, respectively), but not by olmesartan/HCTZ, the difference between the two treatments being statistically significant (p <0.05).	delapril	67-75	insulin	Homo sapiens	7-14	
18310964-10	2008	CONCLUSION: In obese hypertensive patients the delapril/manidipine combination but not the olmesartan/HCTZ combination significantly decreased insulin resistance and plasma fibrinogen levels, despite the similar BP lowering efficacy.	delapril	47-55	insulin	Homo sapiens	143-150	
8877275-0	1996	Effect of manidipine and delapril on insulin sensitivity in type 2 diabetic patients with essential hypertension.	delapril	25-33	insulin	Homo sapiens	37-44	
18310964-0	2008	Effect of delapril/manidipine vs olmesartan/ hydrochlorothiazide combination on insulin sensitivity and fibrinogen in obese hypertensive patients.	delapril	10-18	insulin	Homo sapiens	80-87	
8877275-1	1996	The open trial was designed to evaluate the effects of long-term antihypertensive treatment with the calcium-channel blocker, manidipine and the angiotensin converting enzyme (ACE) inhibitor, delapril on insulin sensitivity in Japanese non-insulin dependent diabetes mellitus (NIDDM) patients with essential hypertension.	delapril	192-200	insulin	Homo sapiens	204-211	
8174845-4	1994	In comparison, intravenous administration of an active metabolite of delapril (3.0 mmol.kg-1) and oral administration of either delapril or enalapril (5.0 mmol.kg-1) showed slight, but not significant increases in insulin sensitivity indices and plasma bradykinin concentrations.	delapril	69-77	insulin	Homo sapiens	214-221